A5048116496- Mosquito-borne diseases and control
- Viral Infections and Vectors
- Malaria Research and Control
- Insect symbiosis and bacterial influences
- Hepatitis B Virus Studies
- Viral Infections and Outbreaks Research
- Nanowire Synthesis and Applications
- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- T-cell and B-cell Immunology
- Cytomegalovirus and herpesvirus research
- Immune Cell Function and Interaction
- Glycosylation and Glycoproteins Research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Hepatitis C virus research
- Virus-based gene therapy research
- HIV Research and Treatment
- Viral Infectious Diseases and Gene Expression in Insects
- vaccines and immunoinformatics approaches
- Viral gastroenteritis research and epidemiology
Integral Molecular (United States)
2020-2025
Vall d'Hebron Institute of Oncology
2024-2025
Vall d'Hebron Hospital Universitari
2024
Universitat Autònoma de Barcelona
2022
Vall d'Hebron Institut de Recerca
2022
Centro de Investigación Biomédica en Red de Cáncer
2022
Abstract Antibody cocktails represent a promising approach to prevent SARS-CoV-2 escape. The determinants for selecting antibody combinations and the mechanism that viral escape remain unclear. We compared critical residues in receptor-binding domain (RBD) used by multiple neutralizing antibodies identified combination of two CoV2-06 CoV2-14 preventing simultaneously bind non-overlapping epitopes independently compete receptor binding. rapidly escapes from individual generating resistant...
Abstract Monoclonal antibodies (mAbs) against Ebola virus (EBOV) glycoprotein (GP 1,2 ) are the standard of care for disease (EVD). Anti-GP mAbs targeting stalk and membrane proximal external region (MPER) potently neutralize EBOV in vitro protective a mouse model EVD. However, their neutralization mechanism is poorly understood because they target GP epitope that has evaded structural characterization. Using X-ray crystallography cryo-electron tomography mAb 3A6 complexed with its...
Abstract Background: Clinical implementation of Chimeric Antigen Receptor (CAR) T cells in solid tumors has been more challenging than for hematological malignancies due part to "on-target, off-tumor" toxicities. The tyrosine-kinase receptor HER2 is a potent oncogene amplified almost 3% all cancers. While most HER2-positive diagnosed at early stages have already effective and available treatment, refractory metastatic still pose an unmet medical need. p95HER2, truncated version the HER2,...
Antibody-mediated humoral immunity is thought to play a central role in mediating the immunopathogenesis of acute DENV infection, but limited data are available on diversity, specificity, and functionality antibody response at molecular level elicited by primary or secondary infection. In order close this functional gap our understanding DENV-specific immunity, we utilized high-throughput single cell RNA sequencing investigate B cells circulating both natural infections. We captured...
Abstract Dengue virus (DENV), from the genus flavivirus of family flaviviridae , causes serious health problems globally. Human monoclonal antibodies (HuMAb) can be used to elucidate mechanisms neutralization and antibody-dependent enhancement (ADE) DENV infections, leading development a vaccine or therapeutic antibodies. Here, we generated eight HuMAb clones an Indonesian patient infected with DENV. These HuMAbs exhibited typical characteristics weak neutralizing including high...
The original version of this Article contained an error in the Acknowledgements, which incorrectly listed NIH grant ‘AI142759’. This has been corrected both PDF and HTML versions Article.
The redirection of T lymphocytes against tumor-associated or tumor-specific antigens, using bispecific antibodies chimeric antigen receptors (CAR), has shown therapeutic success certain hematological malignancies. However, this strategy not been effective solid tumors. Here, we describe the development CAR cells targeting p95HER2, a found in HER2-amplified These display robust activity p95HER2-expressing cell lines but demonstrate limited efficacy patient-derived xenografts. As p95HER2 is...
The development of vaccines against flaviviruses, including Zika virus (ZIKV) and dengue (DENV), continues to be a major challenge, hindered by the lack efficient reliable methods for screening neutralizing activity sera or antibodies. To address this need, we previously developed plasmid-based, replication-incompetent DENV reporter particle (RVP) production system as an safe alternative Plaque Reduction Neutralization Test (PRNT). As part response 2015–2016 ZIKV outbreak, pseudo-infectious...
Three clinically relevant ebolaviruses - Ebola (EBOV), Bundibugyo (BDBV), and Sudan (SUDV) viruses, are responsible for severe disease occasional deadly outbreaks in Africa. The largest virus (EVD) epidemic to date 2013-2016 West Africa highlighted the urgent need countermeasures, leading development FDA approval of vaccine rVSV-ZEBOV (Ervebo®) 2020 two monoclonal antibody (mAb)-based therapeutics (Inmazeb® [atoltivimab, maftivimab, odesivimab-ebgn] Ebanga® (ansuvimab-zykl) 2020. humoral...
Abstract Monoclonal antibodies (mAbs) against Ebola virus (EBOV) glycoprotein (GP 1,2 ) are the standard of care for disease (EVD). Anti-GP mAbs targeting stalk and membrane proximal external region (MPER) potently neutralize EBOV in vitro . However, their neutralization mechanism is poorly understood because they target a GP epitope that has evaded structural characterization. Moreover, vivo efficacy only been evaluated mouse model EVD. Using x-ray crystallography cryo-electron tomography...
Abstract Redirection of T lymphocytes against tumor-associated or tumor-specific antigens, via bispecifc cells engagers (BiTEs) chimeric antigen receptors (CARs), is a successful therapeutic strategy certain hematologic malignancies. In contrast, so far it has failed solid tumors. Given the scarcity vast majority BiTEs and CAR Ts developed to date have been directed antigens. These are expressed in some normal tissues and, as consequence, frequent serious side effects caused by on-target...
Zika virus (ZIKV), a mosquito-transmitted flavivirus, caused large epidemic in Latin America between 2015 and 2017. Effective ZIKV vaccines treatments are urgently needed to prevent future epidemics severe disease sequelae. People infected with develop strongly neutralizing antibodies linked viral clearance durable protective immunity. To understand the mechanisms of immunity support development vaccines, we characterize here antibody, B11F, isolated from patient who recovered ZIKV. Our...
ABSTRACT The development of vaccines against flaviviruses, including Zika virus (ZIKV) and dengue (DENV), continues to be a major challenge, hindered by the lack efficient reliable methods for screening neutralizing activity sera or antibodies. To address this need, we previously developed plasmid-based, replication-incompetent DENV reporter particle (RVP) production system as an safe alternative Plaque Reduction Neutralization Test (PRNT). As part response 2015-2016 ZIKV outbreak, recently...
Abstract Dengue virus (DENV), from the genus flavivirus of family flaviviridae , causes serious health problems globally. Human monoclonal antibodies (HuMAb) can be used to elucidate mechanisms neutralization and antibody-dependent enhancement (ADE) DENV infections, leading development a vaccine or therapeutic antibodies. Here, we generated eight HuMAb clones an Indonesian patient infected with DENV. These HuMAbs exhibited typical characteristics weak neutralizing including high...
Abstract Zika virus (ZIKV), a mosquito-transmitted flavivirus, caused large epidemic in Latin America between 2015 and 2017. Effective ZIKV vaccines treatments are urgently needed to prevent future epidemics severe disease sequelae. People infected with develop strongly neutralizing antibodies linked viral clearance durable protective immunity. To understand mechanisms of immunity support the development vaccines, here we characterize properties antibody, B11F, isolated from recovered...